NCT06960577

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date: May 15, 2025
Primary completion: Oct 31, 2028
Completion date: Oct 31, 2028
First posted: May 7, 2025
Last posted: Nov 24, 2025
Enrollment: 150
Arms / groups: 2 / —
Source: AACT · ctgov ingestion

Drugs studied

doxorubicin
durvalumab
gemcitabine
vinblastine
methotrexate
cisplatin
prednisolone

Indications studied

Immune Checkpoint Inhibitors
Urinary Bladder Neoplasms
Cisplatin
Doxorubicin
Methotrexate
Vinblastine
Drugs, Investigational

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.

NCT06960577

Timeline

Sponsors

Drugs studied

Indications studied